reports
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (a...
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP) Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic ITP WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of (Sobi®), today an...
- ABGSC Healthcare Research
- Julia Sundvall
- Philip Ekengren
- ABGSC Healthcare Research
- Julia Sundvall
- Philip Ekengren
Swedish Orphan Biovitrum AB: 1 director
A director at Swedish Orphan Biovitrum AB sold 7,723 shares at 288.474SEK and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Healthcare Research
- Julia Sundvall
- Philip Ekengren
FRO - Grant of synthetic options
FRO - Grant of synthetic options Frontline plc ("Frontline" or the "Company") hereby announces that 362,284 synthetic options have today been granted to management and employees of the Company. The synthetic options will have a five-year term expiring May 27, 2030, and will vest over a three-year vesting period as follows: 1/3 of the synthetic options will vest on May 27, 20261/3 of the synthetic options will vest on May 27, 2027 1/3 of the synthetic options will vest on May 27, 2028 The exercise price of the synthetic options is USD 16.8 being the volume-weighted average price of the ...
FRO - Q1 2025 Presentation
FRO - Q1 2025 Presentation Please find enclosed the presentation of Frontline plc´s first quarter 2025 results to be held on the webcast / conference call 23 May, 2025 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 – 12 of the Norwegian Securities Trading Act. Attachment
FRO – First Quarter 2025 Results
FRO – First Quarter 2025 Results FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 Frontline plc (the “Company”, “Frontline,” “we,” “us,” or “our”), today reported unaudited results for the three months ended March 31, 2025: Highlights Profit of $33.3 million, or $0.15 per share for the first quarter of 2025.Adjusted profit of $40.4 million, or $0.18 per share for the first quarter of 2025.Declared a cash dividend of $0.18 per share for the first quarter of 2025.Reported revenues of $427.9 million for the first quarter of 2025.Achieved average daily spot time char...
FRO – Invitation to Q1 2025 Results Conference Call and Webcast
FRO – Invitation to Q1 2025 Results Conference Call and Webcast Frontline plc.’s preliminary first quarter 2025 results will be released on Friday May 23, 2025, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at and follow the “Webcast” link, or access directly from the link below. b. Conference C...
- Patrik Ling
Swedish Orphan Biovitrum (Buy, TP: SEK365.00) - Haemophilia the highli...
Q1 sales beat our forecast by 5% and adj. EBITA outperformed by 8%. Overall, we believe the highlight in the report was the stronger haemophilia result than expected, with solid growth in Altuvoct and a smaller decline for Elocta than forecast. The weak spot was Vonjo sales, which missed our estimate by 28% and consensus by 29%, with management citing stocking issues. We reiterate our BUY and SEK365 target price.
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- Jørgen Lian
Frontline (Buy, TP: NOK280.00) - Front-row ticket to tanker potential
We believe the tanker fundamentals continue to look attractive, in particular for the VLCCs, with a highly manageable ~4% deliveries expected for 2025–2026. Further, we see potential positive catalysts in sanctions further restricting volumes transported on the dark fleet (possibly triggering scrapping postponed by shadow fleet deployment) and signs of a more aggressive volume strategy from OPEC+. Hence, we reiterate our BUY but have reduced out target price to NOK280 (295).
- ABGSC Healthcare Research
- Julia Sundvall
- Stefan Knutsson
- Karl-Johan Bonnevier
Humana (Buy, TP: SEK52.00) - Growth agenda back in focus
The Q1 results were mixed, but with the financials now in good order, we see more of a growth focus ahead. We find management’s priorities logical, with our underlying forecast largely unchanged, but our 2025–2027e EPS cut by 6–2% on FX and non-cash items. We reiterate our BUY, but have trimmed our target price to SEK52 (53), focusing on Humana’s market opportunity, operating profile, financial outlook and valuation.
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- ABGSC Healthcare Research
- Julia Sundvall
- Stefan Knutsson
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.